Randomized Trialhigh evidence
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine·February 8, 2024·PMID 38324483
Why it mattersThis is the first positive phase 3 trial for a NASH therapeutic, demonstrating histological improvement in both steatohepatitis and fibrosis—key endpoints linked to clinical outcomes. It addresses a major unmet need in a disease with no approved pharmacotherapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled